Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693122 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL11540653 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL10722450 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL11229618 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL2304845 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL7663036 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL5802863 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL9119248 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL9868874 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 | |
| SCHEMBL1692351 | 1.00 | CES2 (0.52) | CES2FFAR4FFAR1MAPTCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206937-B1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR THE TREATMENT OF ATOPIC DERMATITIS | SHOEI CO LTD (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | SHOEI CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1206937-A1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS | SHOEI CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | IL4I1, NSD1, CUTA | CES2 2960/4885FFAR4 971/4885FFAR1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.